Provocation After Nurse-Directed Assessment (PANDA) Study
PANDAS
1 other identifier
observational
440
1 country
4
Brief Summary
The study aims to evaluate the effectiveness and safety of a collaborative nurse-allergist approach in penicillin allergy delabeling services. It also seeks to assess the impact on patients' quality of life and compare resource utilization and cost-effectiveness between the nurse-allergist collaborative approach and the traditional allergist-led approach.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2025
Longer than P75 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 10, 2025
CompletedFirst Posted
Study publicly available on registry
August 17, 2025
CompletedStudy Start
First participant enrolled
September 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2029
April 29, 2026
August 1, 2025
2 years
August 10, 2025
April 28, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Delabelling Success Rate
Assess the proportion of low-risk patients who are no longer considered allergic to penicillin after delabeling.
6 months
Secondary Outcomes (5)
Health-Related Quality of Life
6 months
Antibiotic Usage Rate
6 months
Age Group Analysis
6 months
Immunocompetence Status
6 months
Initial vs. Recurrent Labeling
6 months
Study Arms (2)
Nurse-led group
Receive Nurse-led penicillin allergy delabelling service
Allergist-led group
Receive Allergist-led penicillin allergy delabelling service
Interventions
Patients in this group undergo risk assessment and categorization by nurses to identify low-risk individuals for delabeling. For these patients, nurses will collaborate with allergists in the delabeling process.
Patients assigned to this group will undergo risk assessment and delabeling led by allergists for both low-risk and high-risk cases.
Eligibility Criteria
Patients treated at a participating hospital who have a documented penicillin allergy label, are evaluated for penicillin allergy through either the nurse-allergist or allergist-led approach, and have available demographic and clinical data.
You may qualify if:
- Receiving inpatient or outpatient treatment at a participating hospital during the study period;
- Possessing a documented penicillin allergy label;
- Underwent penicillin allergy evaluation by the nurse-allergist collaborative approach or the traditional allergist-led approach
- Demographic and clinical data required for the study available.
You may not qualify if:
- Patients unable to provide a complete medication history or history of penicillin allergy;
- Patients with only emergency or short-term treatment records;
- Patients who have taken steroids, antihistamines, or similar medications within the last 3 days.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Prince of Wales Hospital
Hong Kong, 999077, Hong Kong
Princess Margaret Hospital
Hong Kong, 999077, Hong Kong
Queen Elizabeth Hospital
Hong Kong, 999077, Hong Kong
Queen Mary Hospital
Hong Kong, 999077, Hong Kong
Related Publications (5)
Schnyder B, Pichler WJ. Mechanisms of drug-induced allergy. Mayo Clin Proc. 2009 Mar;84(3):268-72. doi: 10.4065/84.3.268.
PMID: 19252115BACKGROUNDAbrams EM, Khan DA. Diagnosing and managing drug allergy. CMAJ. 2018 Apr 30;190(17):E532-E538. doi: 10.1503/cmaj.171315. No abstract available.
PMID: 29712672BACKGROUNDClassen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997 Jan 22-29;277(4):301-6.
PMID: 9002492BACKGROUNDPourpak Z, Fazlollahi MR, Fattahi F. Understanding adverse drug reactions and drug allergies: principles, diagnosis and treatment aspects. Recent Pat Inflamm Allergy Drug Discov. 2008 Jan;2(1):24-46. doi: 10.2174/187221308783399289.
PMID: 19075990BACKGROUNDPatton K, Borshoff DC. Adverse drug reactions. Anaesthesia. 2018 Jan;73 Suppl 1:76-84. doi: 10.1111/anae.14143.
PMID: 29313907BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof.
Study Record Dates
First Submitted
August 10, 2025
First Posted
August 17, 2025
Study Start
September 1, 2025
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
August 31, 2029
Last Updated
April 29, 2026
Record last verified: 2025-08